Pre-made Tralokinumab benchmark antibody ( Whole mAb, anti-IL13 therapeutic antibody, Anti-IL-13/P600 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Tralokinumab biosimilar, Whole mAb, Anti-IL13 Antibody: Anti-IL-13/P600 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tralokinumab is a human monoclonal antibody which targets the cytokine interleukin 13,[1] and is designed for the treatment of asthma and other inflammatory diseases. Tralokinumab was discovered by Cambridge Antibody Technology scientists, using Ribosome Display, as CAT-354 and taken through pre-clinical and early clinical development. After 2007 it has been developed by MedImmune, a member of the AstraZeneca group, where it is currently in Ph3 testing for asthma and Ph2b testing for atopic dermatitis. This makes it one of the few fully internally discovered and developed drug candidates in AstraZeneca's late stage development pipeline.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-592-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Tralokinumab biosimilar, Whole mAb, Anti-IL13 Antibody: Anti-IL-13/P600 therapeutic antibody
INN Name	Tralokinumab
Target	IL13
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	5l6y:HL
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2009
Year Recommended	2010
Companies	Cambridge Antibody Technology;Icahn School of Medicine at Mount Sinai;LEO Pharma;MedImmune
Conditions Approved	na
Conditions Active	Atopic dermatitis;Alopecia areata
Conditions Discontinued	Asthma;Chronic obstructive pulmonary disease;Idiopathic pulmonary fibrosis;Ulcerative colitis
Development Tech	na